Drugs /

vocimagene amiretrorepvec

Back to Drugs List

Overview

Generic Name(s):
vocimagene amiretrorepvec
NCI Definition [1]:
A replication competent retroviral vector, derived from the Moloney murine leukemia virus (MoMLV), encoding a modified form of the yeast suicide gene cytosine deaminase (CD) (Toca 511) used as an antineoplastic adjuvant. Upon transcranial injection, vocimagene amiretrorepvec preferentially enters and transfects tumor cells, and expresses cytosine deaminase, an enzyme that catalyzes the intracellular conversion of the prodrug flucytosine (5-FC) into the antineoplastic agent 5-fluorouracil (5-FU). After administration of 5-FC, the tumor can be eradicated upon activation of 5-FU.

Clinical Trials

View Clinical Trials for vocimagene amiretrorepvec

Vocimagene amiretrorepvec has been investigated in 2 clinical trials, of which 0 are open and 2 are closed. Of the trials investigating vocimagene amiretrorepvec, 1 is phase 1 (0 open) and 1 is phase 2/phase 3 (0 open).

ABL2 Fusion, ACVR1B Loss, and ACVR1B Mutation are the most frequent biomarker inclusion criteria for vocimagene amiretrorepvec clinical trials.

Anaplastic astrocytoma, bladder carcinoma, and breast carcinoma are the most common diseases being investigated in vocimagene amiretrorepvec clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Vocimagene Amiretrorepvec
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating vocimagene amiretrorepvec and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
toca 511, retroviral virus vector encoding cytosine deaminase, dna (synthetic toca 511-encoding retroviral vector ac3-ycd2(v)), vocimagene amiretrorepvec
NCIT ID [1]:
C91734

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.